Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies

 
• By Alaric DeArment

Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
• Source: Shutterstock

More from Deals

More from Business